Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question
Indaptus Therapeutics announced a $6 million preferred-stock financing with investor David Lazar, who will become chairman and co-CEO. The deal could add up to 111 million common shares if converted, pending shareholder approval. Shares jumped over 60% after hours on December 23, 2025, following the news, after closing at $1.95 in regular trading. Two directors resigned as part of the boardroom changes.
